Biotechnology company Zealand Pharma (NASDAQ:ZEAL) has delivered positive topline results from the Phase 3 trial of glepaglutide for the treatment of short bowel syndrome (SBS).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The trial met its primary endpoint and the twice-weekly dosing regimen showed a statistically significant decrease in weekly parental support at 24 weeks.
The treatment was deemed safe and was well tolerated.
Is Zealand Pharma Stock Good?
The Street currently has a Moderate Buy consensus rating on Zealand stock alongside an average price target of $32 which indicates an 81.92% potential upside for ZEAL stock.
Read full Disclosure